Physician profile
Stefanie Christopher
NPI 1972139566
$1,572.58
in general payments reported to CMS, 2019-2025
19 companies · $88.07 in 2025
The $88.07 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,070 · 2024: $414 · 2025: $88.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.59 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.85 | 2023 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $243.38 | 2023 | |
| Abbvie INC. | $135.02 | 2023-2024 | |
| Lilly USA, LLC | $113.69 | 2023-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $101.15 | 2023-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $78.11 | 2023 | Stelara, Remicade, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $66.96 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $56.86 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.38 | 2023 | |
| Sun Pharmaceutical Industries INC. | $46.62 | 2025 | |
| Celgene Corporation | $45.22 | 2023-2024 | Zeposia |
| Glaxosmithkline, LLC. | $41.45 | 2025 | Shingrix |
| Ardelyx, INC. | $21.55 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $18.47 | 2023 | Ocaliva |
| Qol Medical, LLC | $18.20 | 2023 | Sucraid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $16.89 | 2024 | Idacio |
| Aimmune Therapeutics, INC. | $15.12 | 2024 | |
| Vivus LLC | $15.08 | 2024 | Qsymia |
| Redhill Biopharma INC. | $14.58 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.